Inclusion Criteria:  Severe COPD (FEV ≤ 50% of theoretical values)  stable for at least two months, treated for at least one year with one (or more successively) combination of at least two inhaled drugs: either a Long-Acting Beta2-Adrenergic bronchodilator (LABA) combined with a corticosteroid (CSI), or a LABA combined with a long-acting anti-cholinergic bronchodilator (LAMA), or a triple combination LABA/LAMA/CSI; History of at least one severe COPD exacerbation (treated with antibiotics and / or oral corticosteroid therapy) in the two years preceding the study; Ex-smokers (at least 6 months of withdrawal) or active daily smokers of more than 10 pack-years Severe dyspnea at baseline (mMRC stage ≥ 2) Aged 40-85 years inclusive Fluency in French A signed and dated written informed consent is obtained prior to participation Affiliated to a health insurance plan  Exclusion Criteria:  Severe exacerbation in the 4 months preceding the study Chronic inflammatory disease (rheumatic, etc.) treated with long-term systemic corticosteroid therapy, Long-term oxygen therapy (exclusive ambulatory oxygen therapy is not a non-inclusion criterion) Unstable cardiovascular pathology (right or left heart failure, coronary artery disease); Cancer Pregnant women; Deprived of liberty or under guardianship.